「Leishmaniasis」の版間の差分
ナビゲーションに移動
検索に移動
Vaccipedia.admin (トーク | 投稿記録) |
Vaccipedia.admin (トーク | 投稿記録) |
||
(同じ利用者による、間の13版が非表示) | |||
1行目: | 1行目: | ||
+ | {{TM menu}} | ||
+ | |||
==taxonomy== | ==taxonomy== | ||
*phylum ''Sarcomastigophorea'', class ''Zoomastigophorea'', genus ''Leishmania'' | *phylum ''Sarcomastigophorea'', class ''Zoomastigophorea'', genus ''Leishmania'' | ||
10行目: | 12行目: | ||
==epidemiology== | ==epidemiology== | ||
*700,000 - 1 mil. new cases per year | *700,000 - 1 mil. new cases per year | ||
− | 20,000-30,000 deaths per year | + | *20,000-30,000 deaths per year |
==life cycle== | ==life cycle== | ||
22行目: | 24行目: | ||
*amastigote - 2-4 μm | *amastigote - 2-4 μm | ||
**transform from promastigote and propagate inside macrophage | **transform from promastigote and propagate inside macrophage | ||
+ | **propagetes inside macrophage | ||
+ | **parasitized macrophage finally ruptures and let amasitgote out which eventually by sandfly | ||
**transform to promastigote inside sandfly midgut | **transform to promastigote inside sandfly midgut | ||
*simpler than ''Trypanosoma'' | *simpler than ''Trypanosoma'' | ||
27行目: | 31行目: | ||
*host: human, dog, rodent | *host: human, dog, rodent | ||
− | === | + | ===sandfly=== |
*''Phlebotomus'' spp. | *''Phlebotomus'' spp. | ||
**Eurasian | **Eurasian | ||
33行目: | 37行目: | ||
**Latin America | **Latin America | ||
*Feed during night | *Feed during night | ||
+ | *Bitten site by sandfly produces asymptomatic papule, eventually enlarges to an ulcerated nodule and will be spontaneously healed | ||
− | + | ==visceral leishmania== | |
− | |||
− | |||
− | |||
*most serious | *most serious | ||
*same as Kala-azar | *same as Kala-azar | ||
69行目: | 71行目: | ||
**dog, cattle is reservoir | **dog, cattle is reservoir | ||
− | + | ===diagnosis of visceral leishmania=== | |
*suspect for >2 weeks fever+splenomegaly with geographical relation | *suspect for >2 weeks fever+splenomegaly with geographical relation | ||
*detection of amastigote in smear of bone marrow aspiration, lymph node or spleen aspiration | *detection of amastigote in smear of bone marrow aspiration, lymph node or spleen aspiration | ||
110行目: | 112行目: | ||
− | + | ===post kala-azar dermal leishmanisis (PKDL)=== | |
*skin manifestation after completion of Tx of visceral leishmaniasis | *skin manifestation after completion of Tx of visceral leishmaniasis | ||
**macular type, papular type, nodular type | **macular type, papular type, nodular type | ||
125行目: | 127行目: | ||
**miltefosine for 12 weeks | **miltefosine for 12 weeks | ||
− | + | ==cutaneous leishmania== | |
*most common | *most common | ||
*same as Oriental sore, Chiclero ulcer (in Latin America) | *same as Oriental sore, Chiclero ulcer (in Latin America) | ||
131行目: | 133行目: | ||
*basically self-limited | *basically self-limited | ||
*rarely diffuce or disseminated | *rarely diffuce or disseminated | ||
− | * | + | *700,000-1.2 mil. new cases per year |
− | *Afghanistan, Algeria, Brazil, Colombia | + | *90% of cases are from 7 countries |
+ | **Afghanistan, Pakistan, Iran, Syria, Saudi Arabia, Algeria, Brazil, Colombia | ||
+ | ***completely different from VL countries but Brazil | ||
**imported in Texas, US in 2015 | **imported in Texas, US in 2015 | ||
+ | **cutaneous leishmaniasis by ''L. donovani'' is reported in Sri Lanka | ||
+ | **tends to increase in conflict area, mass displacement, military deployment | ||
+ | ***especially in Syria since its civil war | ||
*''L. tropica'', ''L. mexicana'', ''L. amazonensis'' and other species >20 | *''L. tropica'', ''L. mexicana'', ''L. amazonensis'' and other species >20 | ||
+ | *"old world" Africa and South Asia | ||
+ | *"new world" Latin America | ||
*''Rhombomys opimus'' (great gerbil) is primary reservoir | *''Rhombomys opimus'' (great gerbil) is primary reservoir | ||
− | * | + | ===transmission=== |
+ | *anthroponotic (''L. tropica'') or zoonotic (other species) | ||
+ | *skin contact with active lesion innocuous | ||
+ | *risk factors | ||
+ | **poor quality housing | ||
+ | **male | ||
+ | **younger age <15 y/o | ||
+ | **proximity to forest | ||
+ | **domestic dog ownership | ||
+ | **sleeping in temporary shelters | ||
− | ====diagnosis of cutaneous leishmaniasis | + | ===clinical features=== |
+ | *no life threatening | ||
+ | *significant cosmetic morbidity | ||
+ | **stigmatization | ||
+ | *old world | ||
+ | **dryer, warty, scaly | ||
+ | *new world | ||
+ | **wet, ulcerative | ||
+ | **lymphadenopathy | ||
+ | |||
+ | ====diffuse cutaneous leishmaniasis==== | ||
+ | *rare form of CL | ||
+ | *nodular, papular | ||
+ | |||
+ | ====disseminated CL==== | ||
+ | *rare form of CL | ||
+ | *>10 mixed type skin lesions | ||
+ | *in immunocompromised host | ||
+ | |||
+ | ====leishmania recidivans==== | ||
+ | *by ''L. tropica'' | ||
+ | *new lesions encircling years-old scar | ||
+ | |||
+ | ===diagnosis of cutaneous leishmaniasis=== | ||
*smear of fine needle aspirate or biopsy of skin lesion | *smear of fine needle aspirate or biopsy of skin lesion | ||
+ | **specimen from ulcer margin is the highest yield | ||
+ | **fine needle aspiration cytology is generally better | ||
*serological test is of no use; low sensitivity and variable specificity | *serological test is of no use; low sensitivity and variable specificity | ||
+ | *NAAT is available | ||
− | ===mucocutaneous leishmania== | + | ====DDx of CL==== |
+ | **staphylococcal infection | ||
+ | **streptococcal infection | ||
+ | **mycobacterial ulcer | ||
+ | **fungal ulcer | ||
+ | **cancer | ||
+ | **sarcoidosis | ||
+ | **tropical ulcer - | ||
+ | |||
+ | ==mucocutaneous leishmania== | ||
+ | *only in new world CL | ||
+ | **Bolivia, Brazil, Peru | ||
*same as Espundia, white leprosy | *same as Espundia, white leprosy | ||
*lyphatic or hematogenous dissemination to mucosa in mouth and/or upper respiratory tract, resulted in destruction and deformity of nose, palate, pharynx | *lyphatic or hematogenous dissemination to mucosa in mouth and/or upper respiratory tract, resulted in destruction and deformity of nose, palate, pharynx | ||
*''L. braziliensis'', ''L. panamensis'' | *''L. braziliensis'', ''L. panamensis'' | ||
− | |||
*progressive ever without treatment | *progressive ever without treatment | ||
*secondary bacterial infection | *secondary bacterial infection | ||
+ | *worsening nasal congestion, epistaxis or discharge common | ||
+ | *permanent disfigurement of face | ||
+ | **cleft palate, nasal septum destruction, "Tapir" nose | ||
− | + | ===diagnosis of mucocutaneous leishmaniasis=== | |
*leishmania is scarce in mucosal lesion | *leishmania is scarce in mucosal lesion | ||
**strong local immune response | **strong local immune response | ||
161行目: | 218行目: | ||
==treatment== | ==treatment== | ||
+ | *majority spontaneously healed in 2-15months | ||
+ | *distinguish simple or complex | ||
+ | **complex - | ||
+ | *new world needs more to identify species to anticipate of progression to mucocutaneous CL | ||
+ | |||
+ | |||
*pentavalent antimonial | *pentavalent antimonial | ||
**meglumine antimoniate | **meglumine antimoniate | ||
174行目: | 237行目: | ||
**liquid nitrogen | **liquid nitrogen | ||
*thermotherapy | *thermotherapy | ||
− | **50℃ for | + | **40-42℃ for 3min. |
+ | ***50℃ for 30 sec. | ||
+ | **make second degree burn | ||
+ | |||
+ | |||
+ | *topical application | ||
==vaccine== | ==vaccine== | ||
186行目: | 254行目: | ||
*vector control for sandfly-borne leishmaniasis | *vector control for sandfly-borne leishmaniasis | ||
*destruction of burrows of great gerbil | *destruction of burrows of great gerbil | ||
+ | |||
+ | ==GHIT Fund== | ||
+ | Global Health Innovative Technology Fund | ||
+ | *supported by Japanese Government |
2022年10月15日 (土) 21:41時点における最新版
Navigation Menu |
General issues of Vaccine | |||||||
---|---|---|---|---|---|---|---|
|
General issues of Travel med. | ||||||||
---|---|---|---|---|---|---|---|---|
|
Immunology | |||||||
---|---|---|---|---|---|---|---|
|
Epi & Stats | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Virus | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
COVID-19 | |||||
---|---|---|---|---|---|
|
Bacteria | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Rickettsia | |||||
---|---|---|---|---|---|
|
Protozoa | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Fungi | |||||||
---|---|---|---|---|---|---|---|
|
Nematode (roundworm) | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Trematode (fluke, distoma) | |||||||
---|---|---|---|---|---|---|---|
|
Cestode (tapeworm) | ||||||
---|---|---|---|---|---|---|
|
Medical Zoology | ||||||||
---|---|---|---|---|---|---|---|---|
|
目次
taxonomy
- phylum Sarcomastigophorea, class Zoomastigophorea, genus Leishmania
- Plasmodium belongs to phylum Apicomplexa
morphology
- single flagellum
- kinetoplast - aggregation of DNA
- similar to Trypanosoma
epidemiology
- 700,000 - 1 mil. new cases per year
- 20,000-30,000 deaths per year
life cycle
- parasitize in human macrophage
- promastigote - 10-25 μm
- with flagellum
- transform from amastigote inside sandfly midgut
- proliferate inside midgut
- introduced into human skin directly from sandfly midgut during sandfly bite
- phagocytized by macrophage
- amastigote - 2-4 μm
- transform from promastigote and propagate inside macrophage
- propagetes inside macrophage
- parasitized macrophage finally ruptures and let amasitgote out which eventually by sandfly
- transform to promastigote inside sandfly midgut
- simpler than Trypanosoma
- vector: sandfly
- host: human, dog, rodent
sandfly
- Phlebotomus spp.
- Eurasian
- Lutzomya spp.
- Latin America
- Feed during night
- Bitten site by sandfly produces asymptomatic papule, eventually enlarges to an ulcerated nodule and will be spontaneously healed
visceral leishmania
- most serious
- same as Kala-azar
- Latin "black fever"
- incubation 3 weeks to > 2 years
- reason of diversity of incubation unknown
- symptoms
- fever -generally low grade
- weight loss
- hepatosplenomegaly - extremely substantial
- completely subsides rapidly by treatment
- cough, diarrhea
- anemia, leukopenia, thrombocytopenia
- many patients are asymptomatic and cured spontaneously
- cell-mediated immunity
- mass treatment of asymptomatic patients is very problematic because of lacking of easily taken oral short course drug
- 50,000-90,000 new cases reported per year 2004-2008
- 202,200-389,100 new cases estimated per year 2004-2008 - underreporting
- mainly children affected
- India, Ethiopia, South Sudan, Uganda, Brazil
- South Asia- decreasing trend towards elimination
- South Asia- epidemic wave pattern every 15 years
- East Africa- no decreasing trends
- East Africa-
- Latin America-
- L. donovani
- India, Africa
- anthroponotic = maintained in human-to-human infection
- L. infantum (formerly L. chagasi was thought separated species)
- Mediterranean, China, South America
- dog, cattle is reservoir
diagnosis of visceral leishmania
- suspect for >2 weeks fever+splenomegaly with geographical relation
- detection of amastigote in smear of bone marrow aspiration, lymph node or spleen aspiration
- sensitivity 93-99% in spleen aspirate, 53-86% in bone marrow aspirate, 53-65% in lymph node aspirate
- 0.1% of life-threatening hemorrhage by spleen aspiration
- sensitivity 93-99% in spleen aspirate, 53-86% in bone marrow aspirate, 53-65% in lymph node aspirate
- culture in NNN media
- immunochromatographical detection of rk39 antigen
- dip stick form
- 97-100% sensitivity in Asia, low in Africa
- reason unkown, possibly the difference of subspecies
- cannot distinguish between active or relapse
- unkown sensitivity in HIV co-infection
- in areas of high HIV prevelence all leischmeniasis patients should be screened for HIV
- PCR
- importance of accurate diagnosis
- clinical features of VL resemble
- DDx
- chronic malaria
- schistosomiasis
- typhoid
- tuberculosis - splenomegaly is rare unless miliary TB
- hematological malignancy
- can be verically transmitted - rare
- Treatment
- to reduce parasite burden
- to improve complication
- to help to induce cell-mediated immunity
- Tx in India
- liposomal AMPH-B
- +miltefosine
- +paromomycin
- +
- AMPH-B - adherence is diffucult
- miltefosine - adherence is diffucult; now is only for combination with liposomal AMPH-B
- drug interactions
- liposomal AMPH-B
- Tx in East Africa
- Tx for L. infantum in Latin America
post kala-azar dermal leishmanisis (PKDL)
- skin manifestation after completion of Tx of visceral leishmaniasis
- macular type, papular type, nodular type
- possibly 5-10% of VL patients
- incidence 4.8/1000 in India
- Leishmania may be detected from skin specimen in some cases
- skin is contagious
- reservoir
- diagnosis
- history of VL
- rK39
- treatment
- no good evidence
- miltefosine for 12 weeks
cutaneous leishmania
- most common
- same as Oriental sore, Chiclero ulcer (in Latin America)
- papule, nodule → ulcer → scar
- basically self-limited
- rarely diffuce or disseminated
- 700,000-1.2 mil. new cases per year
- 90% of cases are from 7 countries
- Afghanistan, Pakistan, Iran, Syria, Saudi Arabia, Algeria, Brazil, Colombia
- completely different from VL countries but Brazil
- imported in Texas, US in 2015
- cutaneous leishmaniasis by L. donovani is reported in Sri Lanka
- tends to increase in conflict area, mass displacement, military deployment
- especially in Syria since its civil war
- Afghanistan, Pakistan, Iran, Syria, Saudi Arabia, Algeria, Brazil, Colombia
- L. tropica, L. mexicana, L. amazonensis and other species >20
- "old world" Africa and South Asia
- "new world" Latin America
- Rhombomys opimus (great gerbil) is primary reservoir
transmission
- anthroponotic (L. tropica) or zoonotic (other species)
- skin contact with active lesion innocuous
- risk factors
- poor quality housing
- male
- younger age <15 y/o
- proximity to forest
- domestic dog ownership
- sleeping in temporary shelters
clinical features
- no life threatening
- significant cosmetic morbidity
- stigmatization
- old world
- dryer, warty, scaly
- new world
- wet, ulcerative
- lymphadenopathy
diffuse cutaneous leishmaniasis
- rare form of CL
- nodular, papular
disseminated CL
- rare form of CL
- >10 mixed type skin lesions
- in immunocompromised host
leishmania recidivans
- by L. tropica
- new lesions encircling years-old scar
diagnosis of cutaneous leishmaniasis
- smear of fine needle aspirate or biopsy of skin lesion
- specimen from ulcer margin is the highest yield
- fine needle aspiration cytology is generally better
- serological test is of no use; low sensitivity and variable specificity
- NAAT is available
DDx of CL
- staphylococcal infection
- streptococcal infection
- mycobacterial ulcer
- fungal ulcer
- cancer
- sarcoidosis
- tropical ulcer -
mucocutaneous leishmania
- only in new world CL
- Bolivia, Brazil, Peru
- same as Espundia, white leprosy
- lyphatic or hematogenous dissemination to mucosa in mouth and/or upper respiratory tract, resulted in destruction and deformity of nose, palate, pharynx
- L. braziliensis, L. panamensis
- progressive ever without treatment
- secondary bacterial infection
- worsening nasal congestion, epistaxis or discharge common
- permanent disfigurement of face
- cleft palate, nasal septum destruction, "Tapir" nose
diagnosis of mucocutaneous leishmaniasis
- leishmania is scarce in mucosal lesion
- strong local immune response
- serology or molecular
emerging novel leishmaniasis
- in Thailand
- L. siamensis, L. martiniquensis
treatment
- majority spontaneously healed in 2-15months
- distinguish simple or complex
- complex -
- new world needs more to identify species to anticipate of progression to mucocutaneous CL
- pentavalent antimonial
- meglumine antimoniate
- sodium stibogluconate
- amphotericin B
- liposomal amphotericin B
- paromomycin
- pentamidine
- miltefosine
- cryotherapy
- liquid nitrogen
- thermotherapy
- 40-42℃ for 3min.
- 50℃ for 30 sec.
- make second degree burn
- 40-42℃ for 3min.
- topical application
vaccine
- no human vaccine
- canine vaccine has been rolled out
- "leishmanization" in Uzbeskistan
- intradermal inoculation of live wild strain of L. major
control
- case detection and treatment for anthroponotic leishmaniasis
- vector control for sandfly-borne leishmaniasis
- destruction of burrows of great gerbil
GHIT Fund
Global Health Innovative Technology Fund
- supported by Japanese Government